The amount of “big” data generated in clinical oncology, whether from molecular, imaging,
pharmacological, or biological origin, brings novel challenges. To mine efficiently this source …

Introduction: Pharmacometric models represent the most comprehensive approaches for
extracting, summarizing and integrating information obtained in the often sparse, limited …

Combinations of therapies are being actively pursued to expand therapeutic options and
deal with cancer's pervasive resistance to treatment. Research efforts to discover effective …

Bevacizumab is the first-in-class antiangiogenic drug and is almost always administrated in
combination with cytotoxics. Reports have shown that bevacizumab could induce a transient …

Concomitant administration of bevacizumab and pemetrexed‐cisplatin is a common
treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC). Vascular …

Background. Since several decades, the experiments have highlighted the analogy of fusing
cell aggregates with liquid droplets. The physical macroscopic models have been derived …

Despite the recent approval of third-generation therapies, overcoming resistance to
epidermal growth factor receptor (EGFR) inhibitors remains a major challenge in non-small …

Experimental evidence suggests that antiangiogenic therapy gives rise to a transient
window of vessel normalization, within which the efficacy of radiotherapy and chemotherapy …

Adequate energy intake and homeostasis are fundamental for the appropriate growth and
maintenance of an organism; the presence of a tumor can break this equilibrium. Tumor …

Mathematical models used in preclinical drug discovery tend to be empirical growth laws.
Such models are well suited to fitting the data available, mostly longitudinal studies of tumor …